Cardiovascular risk in systemic lupus erythematosus - Evidence of increased oxidative stress and dyslipidaemia

Rheumatology

Volumn 42, Issue 6, 2003, Pages 758-762

  Nuttall, S L ^a   Heaton, S ^a   Piper, M K ^a   Martin, U ^a   Gordon, C ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Cardiovascular risk; LDL subfractions; Lupus; Oxidative stress

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CHOLESTEROL; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PREDNISOLONE; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; AGE; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; FRACTIONATION; GENDER; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL; VENOUS BLOOD; BLOOD; HYPERLIPIDEMIA; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL; FEMALE; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS, LDL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; OXIDATIVE STRESS; RISK FACTORS; TRIGLYCERIDES;

EID: 0037926697     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg212     Document Type: Article

References (33)

1. Uramoto KM, Michet CJ, Thumboo J, Sunku J, O'Fallon WM, Gabriel SE. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999;42:46-50.
2. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 2000;9:170-5.
3. Manzi S, Meilahn EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145:408-15.
4. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996;348:1120-4.
5. Kendall MJ, Nuttall SL. Anti-oxidant therapy for the treatment of coronary artery disease. Expert Opin Investig Drugs 1999;8:1763-84.
6. Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Arthritis Rheum 1995; 38:551-8.
7. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
8. Gladman DD, Urowitz MB, Goldsmith CH et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809-13.
9. Hay EM, Bacon PA, Gordon C et al. The BILAG index: a reliable and valid instrument for measuring clinic disease activity in systemic lupus erythematosus. Q J Med 1993; 86:447-58.
10. Rajman I, Kendall MJ, Cramb R, Holder R, Alih M, Gammage MD. Investigation of LDL subfraction profile as a coronary risk factor in normotriglyceridaemic men. Atherosclerosis 1996;125:231-42.
11. Whitehead TP, Thorpe GHG, Maxwell SRJ. Enhanced chemiluminescent assay for antioxidant capacity in biological fluids. Anal Chim Acta 1992;266:265-77.
12. Nourooz-Zadeh J, Tajadinni-Sarmadi J, Wolff SP. Measurement of plasma hydroperoxide concentrations by the ferrous oxidation-xylenol orange assay in conjunction with triphenylphosphine. Anal Biochem 1994; 220:403-9.
13. Peakman M, Loboyeo A, Senaldi G et al. Quantification of c3d in biological fluids by an enzyme-linked immunoabsorbent-assay. J Immunol Methods 1987; 104:51-6.
14. Hurt-Camejo E, Paredes S, Masana L, Camejo G, Sartipy P, Rosengren B. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis. Arthritis Rheum 2001;44:2761-7.
15. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-3.
16. Danesh J, Whincup P, Walker M et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Br Med J 2000; 321:199-204.
17. Ridker PM, Rifai N, Stampfer M, Hennekens CH. Plasma concentrations of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767-72.
18. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. The FRISC Study Group markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med 2000;343:1139-47.
19. Manzi S. Systemic lupus erythematosus: a model for atherogenesis? Rheumatology 2000;39:353-9.
20. Manzi S, Selzer F, Sutton-Tyrrell K et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:51-60.
21. Svenungsson E, Jensen-Urstad K, Heimbürger M et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001;104:1887-93.
22. Ames PRJ, Alves J, Murat I, Isenberg DA, Nourooz-Zadeh J. Oxidative stress in systemic lupus erythematosus and allied conditions with vascular involvement. Rheumatology 1999; 38:529-34.
23. Vaarala O. Antibodies to oxidised LDL. Lupus 2000; 9:202-5.
24. Iuliano L, Pratico D, Ferro D et al. Enhanced lipid peroxidation in patients positive for antiphospholipid antibodies. Blood 1997;90:3931-5.
25. Bulkley HB, Roberts WC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. Am J Med 1975;58:243-64.
26. Bruce IN, Gladman DD, Urowitz MB. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2000;26:257-78.
27. Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990;89:322-6.
28. Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994;96:254-9.
29. Rahman P, Gladman DD, Urowitz MB, Yuen K, Hallett D, Bruce IN. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 1999;26:325-30.
30. Wierzbicki AS. Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus. Lupus 2000; 9:194-201.
31. Libby P. What have we learned about the biology of atherosclerosis? The role of inflammation. Am J Cardiol 2001;88:3J-6J.
32. Piper MJ, Heaton SJ, Gardner-Medwin JM, Townend J, Bacon PA, Gordon C. A study of endothelial function in systemic lupus erythematosus (SLE). Rheumatology 2001;40(Suppl. 1):113.
33. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948-54.